MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer

被引:51
|
作者
Goorts, Briete X. Z. [1 ,2 ,3 ]
Dreuning, Kelly M. A. [2 ]
Houwers, Janneke B. [3 ]
Kooreman, Loes F. S. [1 ,4 ]
Boerma, Evert-Jan G. [5 ]
Mann, Ritse M. [6 ]
Lobbes, Marc B. I. [1 ,3 ]
Smidt, Marjolein L. [1 ,2 ]
机构
[1] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands
[2] Maastricht Univ, Med Ctr, Dept Surg, Maastricht, Netherlands
[3] Maastricht Univ, Med Ctr, Dept Radiol & Nucl Med, POB 5800, NL-6202 AZ Maastricht, Netherlands
[4] Maastricht Univ, Med Ctr, Dept Pathol, Maastricht, Netherlands
[5] Zuyderland Med Ctr, Dept Surg, Sittard Geleen, Netherlands
[6] Radboud Univ Nijmegen, Med Ctr, Dept Radiol & Nucl Med, Nijmegen, Netherlands
来源
BREAST CANCER RESEARCH | 2018年 / 20卷
关键词
Breast Cancer; Neoadjuvant chemotherapy; Magnetic resonance imaging; RECOMMENDATIONS; THERAPY; UPDATE; TRIAL;
D O I
10.1186/s13058-018-0950-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The main purpose was to investigate the correlation between magnetic resonance imaging (MRI)-based response patterns halfway through neoadjuvant chemotherapy and immunotherapy (NAC) and pathological tumor response in patients with breast cancer. Secondary purposes were to compare the predictive value of MRI-based response patterns measured halfway through NAC and after NAC and to measure interobserver variability.& para;& para;Methods: All consecutive patients treated with NAC for primary invasive breast cancer from 2012 to 2015 and who underwent breast MRI before, halfway through (and after) NAC were included. All breast tumors were reassessed on MRI by two experienced breast radiologists and classified into six patterns: type 0 (complete radiologic response); type 1 (concentric shrinkage); type 2 (crumbling); type 3 (diffuse enhancement); type 4 (stable disease); type 5 (progressive disease). Percentages of tumors showing pathological complete response (pCR), > 50% tumor reduction and > 50% tumor diameter reduction per MRI-based response pattern were calculated. Correlation between MRI-based response patterns and pathological tumor reduction was studied with Pearson's correlation coefficient, and interobserver agreement was tested with Cohen's Kappa.& para;& para;Results: Patients (n = 76; mean age 53, range 29-72 years) with 80 tumors (4 bilateral) were included. There was significant correlation between these MRI-based response patterns halfway through NAC and tumor reduction on pathology assessment (reader 1 r = 0.33; p = 0.003 and reader 2 r = 0.45; p < 0.001). Type-0, type-1 or type-2 patterns halfway through NAC showed highest tumor reduction rates on pathology assessment, with > 50% tumor reduction in 90%, 78% and 65% of cases, respectively. In 83% of tumors with type 0 halfway through NAC, pathology assessment showed pCR. There was no significant correlation between MRI-based response patterns after NAC and tumor reduction rates on pathology assessment (reader 1 r = - 0.17; p = 0.145 and reader 2 r = - 0.17; p = 0.146). In 41% of tumors with type 0 after NAC, pathology assessment showed pCR.& para;& para;Conclusion: MRI-based response patterns halfway through NAC can predict pathologic response more accurately than MRI-based response patterns after NAC. Complete radiological response halfway NAC is associated with 83% pCR, while complete radiological response after NAC seems to be correct in only 41% of cases.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Longitudinal MRI-based fusion novel model predicts pathological complete response in breast cancer treated with neoadjuvant chemotherapy: a multicenter, retrospective study
    Huang, YuHong
    Zhu, Teng
    Zhang, XiaoLing
    Li, Wei
    Zheng, XingXing
    Cheng, MinYi
    Ji, Fei
    Zhang, LiuLu
    Yang, CiQiu
    Wu, ZhiYong
    Ye, GuoLin
    Lin, Ying
    Wang, Kun
    ECLINICALMEDICINE, 2023, 58
  • [22] Computer-aided classification of MRI for pathological complete response to neoadjuvant chemotherapy in breast cancer
    Yan, Shaolei
    Peng, Haiyong
    Yu, Qiujie
    Chen, Xiaodan
    Liu, Yue
    Zhu, Ye
    Chen, Kaige
    Wang, Ping
    Li, Yujiao
    Zhang, Xiushi
    Meng, Wei
    FUTURE ONCOLOGY, 2022, 18 (08) : 991 - 1001
  • [23] Can The Neutrophil To Lymphocyte Ratio Predict Complete Pathological Response To Neoadjuvant Therapy In Breast Cancer?
    Cullinane, C.
    Creavin, B.
    Corrigan, M.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2019, 188 : S181 - S182
  • [24] Can a pathological complete response after neoadjuvant chemotherapy in breast cancer patients be diagnosed by minimal invasive biopsy?
    Heil, J.
    Schaefgen, B.
    Sinn, P.
    Richter, H.
    Harcos, A.
    Gomez, C.
    Stieber, A.
    Hennigs, A.
    Rauch, G.
    Schneeweiss, A.
    Schuetz, F.
    Sohn, C.
    Golatta, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 168 - 168
  • [25] Biomarkers Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
    Li, Xiaoxian
    Krishnamurti, Uma
    Bhattarai, Shristi
    Klimov, Sergey
    Reid, Michelle
    Aneja, Ritu
    LABORATORY INVESTIGATION, 2016, 96 : 54A - 54A
  • [26] Biomarkers Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
    Li, Xiaoxian
    Krishnamurti, Uma
    Bhattarai, Shristi
    Klimov, Sergey
    Reid, Michelle
    Aneja, Ritu
    MODERN PATHOLOGY, 2016, 29 : 54A - 54A
  • [27] Prediction of pathological complete response by microRNA in breast cancer patients treated with neoadjuvant chemotherapy
    Shimomura, Akihiko
    Shiino, Sho
    Kawauchi, Junpei
    Takizawa, Satoko
    Ichikawa, Makiko
    Matsuzaki, Juntaro
    Sakamoto, Hiromi
    Kinoshita, Takayuki
    Tamura, Kenji
    Ochiya, Takahiro
    CANCER SCIENCE, 2018, 109 : 394 - 394
  • [28] Performances of breast magnetic resonance imaging in the context of neoadjuvant chemotherapy for breast cancer to predict pathological complete response
    Brisson, C.
    Diguisto, C.
    Vilde, A.
    Body, G.
    Arbion, F.
    Leveque, J.
    Ouldamer, L.
    JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION, 2017, 46 (02) : 147 - 154
  • [29] Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?
    B. Schaefgen
    M. Mati
    H. P. Sinn
    M. Golatta
    A. Stieber
    G. Rauch
    A. Hennigs
    H. Richter
    C. Domschke
    F. Schuetz
    C. Sohn
    A. Schneeweiss
    Joerg Heil
    Annals of Surgical Oncology, 2016, 23 : 789 - 795
  • [30] Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?
    Schaefgen, B.
    Mati, M.
    Sinn, H. P.
    Golatta, M.
    Stieber, A.
    Rauch, G.
    Hennigs, A.
    Richter, H.
    Domschke, C.
    Schuetz, F.
    Sohn, C.
    Schneeweiss, A.
    Heil, Joerg
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (03) : 789 - 795